Between Necessity and Compliance: Understanding FDA's GFI #256 for Animal Drug Compounding.

Abstract

The practice of compounding animal drugs using bulk drug substances presents a challenging intersection of veterinary need and federal regulatory compliance. Governed by the Federal Food, Drug, and Cosmetic Act ("FDCA"), this area of animal healthcare has long operated in a legal gray zone, with the FDA traditionally exercising discretion in its enforcement. To bring clarity to this nuanced issue, the FDA issued Guidance for Industry #256 ("GFI #256"), which outlines the specific circumstances under which the agency will decline to take enforcement action against compounders of animal drugs using bulk drug substances. This article explores the practical implications of GFI #256 for veterinarians and compounders, focusing on three critical requirements that must be met when compounding bulk drug substances for non-food-producing animals under a patient-specific prescription. stakeholders can better navigate the complex regulatory landscape and ensure their practices align with FDA expectations.